MedTrace Logo

Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design

NCT01945359 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2015-10-16

No results posted yet for this study

Summary

This study will observe participants with relapsing remitting multiple sclerosis who are switching therapies from natalizumab to dimethyl fumarate to determine disease stability.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • Rocky Mountain MS Research Group, LLC

    lead OTHER

Principal Investigators

  • John F Foley, MD · President, Rocky Mountain MS Research Group

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-09-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01945359 on ClinicalTrials.gov